Loading...
Market
Seladelpar's impact on ALP levels in follow-up studies by December 31, 2025
2
Resolution / Starting Odds
ALP normalization in over 30% of patients • 25%
ALP normalization in 20-30% of patients • 25%
ALP normalization in 10-20% of patients • 25%
ALP normalization in less than 10% of patients • 25%
Published results of follow-up clinical studies
Story
Gilead's Seladelpar Gets Positive CHMP Opinion for PBC, Shows 62% Response Rate
Dec 13, 2024, 11:39 AM
Gilead Sciences, Inc. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its drug seladelpar, intended for the treatment of primary biliary cholangitis (PBC) in adults. The recommendation is based on the results from the pivotal placebo-controlled Phase 3 RESPONSE study, which demonstrated that seladelpar achieved a composite biochemical response in 62% of participants at month 12, compared to 20% with placebo. Additionally, 25% of participants on seladelpar normalized their alkaline phosphatase (ALP) levels, a key marker of disease progression in PBC. The drug also significantly reduced pruritus, a common and debilitating symptom of PBC. If approved by the European Commission, seladelpar would provide an important new treatment option for PBC patients in the EU, where the disease affects approximately 15 per 100,000 people, primarily women.
View original story
Similar markets
FDA approval granted • 25%
FDA approval denied • 25%
Further trials required • 25%
Withdrawn by Gilead • 25%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Phase II trial results • 25%
Phase III trial initiation • 25%
New partnership announcement • 25%
Other • 25%
Phase 3 trial initiation • 25%
FDA breakthrough therapy designation • 25%
Partnership with a major pharma • 25%
Other milestone • 25%
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
